Ozempic for PCOS: What You Need to Know

Polycystic ovary syndrome (PCOS) affects an estimated 10–13% of women worldwide, according to the WHO, and up to 70% of those affected do not know they have it. The NHS now uses a newer name for the condition, PMOS, though PCOS is still widely used.

The exact cause of PCOS is unknown, but insulin resistance plays a major role for many people. Together with other hormonal changes, this can cause irregular periods, elevated androgens, many small follicles on the ovaries, difficulty losing weight, skin changes, hair growth in unwanted areas, and in many cases, difficulty conceiving.

GLP-1 medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) are increasingly prescribed off-label for people with PCOS and higher weight. Here is what the research shows, what to expect, and what to discuss with your doctor.

Understanding PCOS: the insulin resistance connection

To understand why GLP-1 drugs may help with PCOS, it helps to understand one of the hormonal chains involved.

In many women with PCOS, a key problem is insulin resistance. The body's cells do not respond normally to insulin. The pancreas compensates by producing more insulin — leading to chronically elevated insulin levels (hyperinsulinaemia).

High insulin then triggers a cascade:

1. Ovaries overproduce androgens (male hormones, primarily testosterone) in response to elevated insulin signals
2. Elevated androgens disrupt the menstrual cycle — interfering with normal ovulation and follicle development
3. Multiple small follicles accumulate on the ovaries (the "cysts" in polycystic)
4. Hormonal feedback loops become dysregulated — LH is often elevated, FSH relatively suppressed

The result is the cluster of symptoms most women with PCOS recognise: irregular or absent periods, acne, excess facial or body hair (hirsutism), difficulty losing weight, and often difficulty conceiving.

The weight-PCOS feedback loop

Weight gain worsens insulin resistance, which worsens PCOS. PCOS makes weight management harder through metabolic changes. This creates a frustrating cycle that many women describe as feeling impossible to break without help.

GLP-1 medications may help break that cycle, mainly by supporting weight loss.

Why GLP-1 drugs may help with PCOS

GLP-1 receptor agonists act on several of the mechanisms linked to PCOS:

• Support weight loss — which reduces insulin resistance
• Lower fasting insulin levels — which may ease the hyperinsulinaemia → androgen overproduction chain
• Improve blood sugar control — through glucose-dependent insulin release and lower glucagon
• Slow gastric emptying — smoothing post-meal blood sugar spikes

These effects target the metabolic side of PCOS, though they are not a cure and do not treat every feature of the condition.

What does the research show?

A number of studies have examined GLP-1 drugs in women with PCOS, but most are small and short. A 2024 systematic review done to inform the international PCOS guideline found 11 trials of anti-obesity medicines in PCOS; liraglutide and semaglutide appeared better than placebo for weight, but the authors said published data were very limited.

Semaglutide and liraglutide trials in PCOS

Small studies using semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda) in women with PCOS have reported:

Insulin sensitivity:

• Significant reduction in fasting insulin levels
• Improved HOMA-IR (a standard measure of insulin resistance)

Androgen levels:

• Reduction in free and total testosterone
• Changes in SHBG (sex hormone-binding globulin) that reduce biologically active androgen levels

Menstrual cycle regularity:

• In multiple studies, a subset of participants experienced more regular cycles, including women who had previously had very infrequent periods
• This effect was most pronounced in women who also lost meaningful body weight

Weight:

• In large obesity trials (not PCOS-specific), average weight loss ranged from about 5% to over 20% depending on the medicine and dose — often above the 5–10% range linked to PCOS improvement

Quality of life:

• Some small studies report improved quality of life, but evidence on mood and energy in PCOS is limited

Ongoing formal PCOS trials

Larger clinical trials of GLP-1 medicines in PCOS are being run (you can search them on ClinicalTrials.gov). As of October 2026, no GLP-1 medicine is approved specifically for PCOS.

How much weight loss helps with PCOS symptoms?

Modest weight loss — often quoted as 5–10% of body weight — can improve some PCOS features in people with higher weight, such as insulin sensitivity and cycle regularity. Responses vary a lot between people, and there is no reliable table of which benefit comes at which amount of weight loss.

The NHS advises trying to lose weight if you are overweight and lists weight loss medicines as one possible treatment. GLP-1 medications often produce weight loss in or above this range when used at full doses and tolerated over time, but they are not a guaranteed fix, and healthy eating and activity help PCOS even without weight loss.

PCOS and fertility: what you need to know

Improving fertility is one of the most common goals women with PCOS bring to their doctors. The connection between GLP-1 therapy and fertility is real — but it comes with an important caveat.

How GLP-1 may support fertility

• Weight loss and improved insulin sensitivity can restore ovulation in women with PCOS who were previously anovulatory
• More regular cycles provide a more predictable fertility window
• Lower androgen levels improve the hormonal environment for egg development
• Some women have reported unexpected pregnancies after starting GLP-1 therapy following years of irregular cycles, so use reliable contraception if you do not want to become pregnant

The critical stop-before-conception rule

GLP-1 medications must be stopped before trying to conceive. The prescribing information for semaglutide (Ozempic, Wegovy) says to stop at least two months before a planned pregnancy; the UK prescribing information for tirzepatide (Mounjaro) says at least one month.

Animal studies showed potential developmental risks at high doses, and human safety data during pregnancy is limited. The FDA has not approved any GLP-1 medication for use during pregnancy.

If improving fertility is part of your goal, this timing matters. The most common approach:

1. Use GLP-1 therapy, with reliable contraception, to achieve metabolic improvement and weight loss
2. Review fertility plans with your doctor once you are at a stable dose
3. When ready to attempt conception, stop the medication with your doctor's guidance, at least 2 months before trying for semaglutide (1 month for tirzepatide in the UK)
4. Pursue fertility support with improved baseline metabolic health

Discuss the full picture with both your prescribing doctor and, if fertility is the primary goal, a reproductive endocrinologist.

Mounjaro (tirzepatide) for PCOS

Mounjaro (tirzepatide) is increasingly used off-label for PCOS and may offer additional benefits over semaglutide alone.

Tirzepatide activates both GLP-1 and GIP receptors. The GIP component may have effects on fat cell metabolism and insulin sensitivity beyond what GLP-1 alone achieves, though this is still being studied.

In the head-to-head SURMOUNT-5 trial in adults with obesity but without diabetes (not PCOS-specific), tirzepatide led to an average weight loss of 20.2% at 72 weeks, compared with 13.7% for semaglutide. For women with PCOS where weight loss is a key lever for hormonal improvement, this additional efficacy may be significant.

Contraception on tirzepatide: tirzepatide can make the contraceptive pill less reliable. Its prescribing information advises switching to a non-oral method or adding a barrier method such as condoms for 4 weeks after starting and for 4 weeks after each dose increase.

Head-to-head PCOS-specific trials comparing semaglutide and tirzepatide have not yet reported. In practice, many doctors choose based on patient preference, insurance coverage, and individual tolerability.

Metformin vs GLP-1 for PCOS

Metformin has been the standard pharmacological treatment for insulin resistance in PCOS for decades. It is inexpensive, well-studied, and widely available.

For some women, particularly those with higher weight, GLP-1 drugs may offer a larger metabolic effect, though direct comparisons in PCOS are limited. In some cases, combining metformin with a GLP-1 medication provides the broadest benefit.

Your doctor will guide the right choice based on your individual profile.

Tracking PCOS symptoms on GLP-1 therapy

PCOS improvements happen over weeks and months, not days. Keeping a consistent record of the following helps you and your doctor evaluate whether the medication is producing the expected hormonal and metabolic benefit:

• Cycle regularity: Track the start date of each period and the length of each cycle
• Energy and mood: Note changes in fatigue, brain fog, and mood week by week
• Skin and hair: Gradual changes in acne, oiliness, or hirsutism often take 3–6 months to appear
• Weight trend: Weekly, not daily — GLP-1 weight loss fluctuates day to day
• Blood markers: Request HbA1c, fasting insulin, HOMA-IR, free and total testosterone at baseline and every 3–6 months

Connecting these data points in one place — rather than across separate apps, notebooks, and memory — makes it much easier to see whether the treatment is working and what to discuss at your next appointment.

What to discuss with your doctor

Before starting or continuing GLP-1 therapy for PCOS:

• Get baseline bloodwork: Fasting insulin, HOMA-IR, HbA1c, LH, FSH, total and free testosterone, SHBG, prolactin, thyroid function
• Set realistic expectations: Hormonal improvements usually take several months; weight loss is often the first measurable change
• Discuss the fertility timeline if relevant — and plan accordingly around stopping the medication
• Ask about the dose: Starting low and escalating slowly improves tolerability
• Ask about safety: GLP-1 medicines carry warnings about pancreatitis and gallbladder problems, and in the US a boxed warning about thyroid C-cell tumours (they should not be used if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2). Seek urgent medical help for severe stomach pain that does not go away (sometimes spreading to your back), or vomiting that stops you keeping fluids down
• Ask about contraception: especially if you use the pill and are prescribed tirzepatide
• Agree on the follow-up plan: When will bloodwork be repeated? What markers define success?

Final takeaway

Ozempic, Wegovy, and Mounjaro are not approved for PCOS, but they can help with weight and insulin resistance, which play a major role in the condition for many people. Small studies and clinical experience suggest improvements in insulin sensitivity, androgen levels and cycle regularity, but larger trials are still needed. The fertility implications require careful planning.

If you have PCOS and overweight or obesity, a detailed conversation with your doctor about GLP-1 therapy is well worth having.

Consult your healthcare provider before starting any medication.

Related Articles

• Obeda for PCOS Weight Loss: Does It Work?
• GLP-1 Drugs and Pregnancy: What You Need to Know
• Long-Term Safety of Semaglutide: What the Evidence Shows

Sources

• Ozempic prescribing information: https://www.novo-pi.com/ozempic.pdf
• Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
• Mounjaro (tirzepatide) UK Summary of Product Characteristics (emc): https://www.medicines.org.uk/emc/product/15481/smpc
• MedlinePlus — semaglutide: https://medlineplus.gov/druginfo/meds/a618008.html
• STEP 1 semaglutide trial — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
• SURMOUNT-5, tirzepatide compared with semaglutide for obesity — PubMed: https://pubmed.ncbi.nlm.nih.gov/40353578/
• Goldberg et al. 2024, anti-obesity agents for PCOS, systematic review for the 2023 international guideline — PubMed: https://pubmed.ncbi.nlm.nih.gov/38355887/
• WHO — Polycystic ovary syndrome fact sheet: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
• NHS — PCOS treatment: https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/treatment/